Sabine Brookman-May, Professor of Urology at Universität München, shared on X:
“Great to finally see the results of the PROTEUS substudy comparing perioperative Apa + ADT with the true SOC (RP w/o neoadjuvant treatment) – which should at least reduce some concerns related to the active comparator with ADT in the main study that didn’t reflect what we actually do as a standard in HR patients.
Outcomes in all endpoints significant improved
- EFS: HR 0.38, 95% CI 0.26–0.55
- MFS: HR 0.49, 95% CI 0.26–0.90
- TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
The question remains which of these outcomes are most clinically relevant and meaningful.”
You may also be interested in:
DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer
